NCT00680914 - Primary Vaccination Course in Children Receiving Pneumococcal Conjugate Vaccine GSK 1024850A or Prevenar™ and Hiberix™ | Biotech Hunter

Enrollment

503

Participants

Timeline

Start Date

June 10, 2008

Primary Completion Date

May 8, 2009

Study Completion Date

May 8, 2009

Conditions

Infections, Streptococcal

Interventions

BIOLOGICAL

Pneumococcal vaccine GSK1024850A (Synflorix)

3 doses administered intramuscularly.

BIOLOGICAL

Prevenar

3 doses administered intramuscularly.

BIOLOGICAL

GSK Biologicals' Hiberix™

3 doses administered intramuscularly.

Trial Locations (14)

425-707

GSK Investigational Site, Ansan

420-767

GSK Investigational Site, Bucheon-si

301-723

GSK Investigational Site, Daejeon

641-560

GSK Investigational Site, Gyeongnam

570-711

GSK Investigational Site, Iksan

690-716

GSK Investigational Site, Jeju City

561-712

GSK Investigational Site, Jeonju Jeonbuk

602-739

GSK Investigational Site, Pusan

130-702

GSK Investigational Site, Seoul

150-719

GSK Investigational Site, Seoul

158-710

GSK Investigational Site, Seoul

411-706

GSK Investigational Site, Seoul

442-723

GSK Investigational Site, Suwon

220-701

GSK Investigational Site, Wonju-si Kangwon-do